Abstract
Anticoagulant drugs are traditionally administered for the prevention and treatment of thrombosis. Besides multi-targeted, traditional anticoagulants, such as coumarins or heparins, the search for the optimal antithrombotic efficacy to bleeding risk ratio has prompted the development of a novel armamentarium of anticoagulant drugs, which is expected to be introduced in the market. These emerging drugs are mainly targeted to suppress the propagation of the coagulation cascade (thrombin burst), by direct thrombin inhibition or selective inhibition of activated factor X. Therefore, thrombin or activated factor X antagonists would produce an efficient anticoagulation while minimizing the risk of bleeding, the most common adverse events of conventional anticoagulants. No routine monitoring, favorable form of administration and better compliance are additional advantages of these innovative drugs, which are already in advanced development or already licensed for clinical use. The aim of this article is to provide an overview on the mechanisms of action, clinical applications, cost-effectiveness and side effects of these emerging anticoagulant strategies.
Keywords: Direct thrombin inhibitors, venous thromboembolism (VTE), Fondaparinux, Rivaroxaban, Heparin
Current Vascular Pharmacology
Title: Antagonists of Activated Factor X and Thrombin: Innovative Antithrombotic Agents.
Volume: 5 Issue: 2
Author(s): Massimo Franchini and Giuseppe Lippi
Affiliation:
Keywords: Direct thrombin inhibitors, venous thromboembolism (VTE), Fondaparinux, Rivaroxaban, Heparin
Abstract: Anticoagulant drugs are traditionally administered for the prevention and treatment of thrombosis. Besides multi-targeted, traditional anticoagulants, such as coumarins or heparins, the search for the optimal antithrombotic efficacy to bleeding risk ratio has prompted the development of a novel armamentarium of anticoagulant drugs, which is expected to be introduced in the market. These emerging drugs are mainly targeted to suppress the propagation of the coagulation cascade (thrombin burst), by direct thrombin inhibition or selective inhibition of activated factor X. Therefore, thrombin or activated factor X antagonists would produce an efficient anticoagulation while minimizing the risk of bleeding, the most common adverse events of conventional anticoagulants. No routine monitoring, favorable form of administration and better compliance are additional advantages of these innovative drugs, which are already in advanced development or already licensed for clinical use. The aim of this article is to provide an overview on the mechanisms of action, clinical applications, cost-effectiveness and side effects of these emerging anticoagulant strategies.
Export Options
About this article
Cite this article as:
Franchini Massimo and Lippi Giuseppe, Antagonists of Activated Factor X and Thrombin: Innovative Antithrombotic Agents., Current Vascular Pharmacology 2007; 5 (2) . https://dx.doi.org/10.2174/157016107780368325
DOI https://dx.doi.org/10.2174/157016107780368325 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Obesity in the Cardiovascular Continuum
Current Clinical Pharmacology Onychomycosis and its Chemotherapy
Current Medicinal Chemistry Pharmacological manipulation of peripheral vascular resistance in special clinical situations after pediatric cardiac surgery
Current Vascular Pharmacology Association of N-Acetyltransferase-2 Genotypes and Anti-Tuberculosis Induced Liver Injury: First Case-Controlled Study from Iran
Current Drug Safety Electron Spin Resonance as a Powerful Tool for Studying Antioxidants and Radicals
Current Medicinal Chemistry An Update on Developments in Female Hormonal Contraception
Current Women`s Health Reviews Vascular Pharmacotherapy and Dementia
Current Vascular Pharmacology Novel Antithrombotic Agents: Indirect Synthetic Inhibitors of Factor Xa and Direct Thrombin Inhibitors. Evidences from Clinical Studies
Current Medicinal Chemistry - Cardiovascular & Hematological Agents A Brief History of ‘Lone’ Atrial Fibrillation: From ‘A Peculiar Pulse Irregularity’ to a Modern Public Health Concern
Current Pharmaceutical Design Human Microdialysis
Current Pharmaceutical Biotechnology Glucose Blood Levels as a Therapeutic Target in Acute Ischaemic Stroke Setting
Current Topics in Medicinal Chemistry Enteral and Parenteral Nutrition Therapy for Crohns Disease
Current Pharmaceutical Design Methylene Blue not Contraindicated in Treating Hemodynamic Instability in Pediatric and Neonate Patients
Current Pediatric Reviews (Phospho)lipid-based Nanosystems for Skin Administration
Current Pharmaceutical Design Targeting RGD Recognizing Integrins: Drug Development, Biomaterial Research, Tumor Imaging and Targeting
Current Pharmaceutical Design Application of Transcranial Color-Coded Duplex Sonography in Stroke Diagnosis
Current Medical Imaging Preventative and Therapeutic Potential of Lipopolysaccharide Derived from Edible Gram-Negative Bacteria to Various Diseases
Current Drug Therapy Designing Phage Therapeutics
Current Pharmaceutical Biotechnology Intrauterine Intervention for the Treatment of Fetal Growth Restriction
Current Pediatric Reviews Focusing the Controversies in Budd-Chiari Syndrome Management
The International Journal of Gastroenterology and Hepatology Diseases